arcabio.com (ABIO) Company Value to Net Income

Symbol and logo of brand ARCA Biopharma, Inc. (ABIO)

ARCA Biopharma (ABIO) develops cardiology treatments via outsourcing at certified US facilities. This chart of current share prices on GURU.Markets shows a value of -4.80. The company's strategy relies on a personalized approach to patient treatment based on their genetics. However, asset mergers and the probability of new drug trial failures create significant financial threats for investors.

P/E Multiple: ARCA Bio (ABIO) for 07/04/2022 - 09/03/2024

Comprehensive metric breakdowns and analytics for ARCA Biopharma (ABIO)

- price and consensus price forecast:
Summary company analysis:ARCA Biopharma
Flagship merchandise of ARCA Bio

The P/E ratio reflects the investment payback period through the lens of current earnings. This coefficient relates the market value of the business to its net income, measuring investment attractiveness. This trend is visualized via the historical P/E chart of the company. For ARCA Biopharma (ABIO), the metric accounts for significant pricing power derived from patents. Inelastic demand for targeted heart failure therapy makes this indicator key to valuing innovations.